Your browser is no longer supported. Please, upgrade your browser.
Settings
ARGX argenx SE daily Stock Chart
ARGX [NASD]
argenx SE
Index- P/E- EPS (ttm)-1.73 Insider Own- Shs Outstand32.45M Perf Week1.21%
Market Cap4.14B Forward P/E- EPS next Y-4.21 Insider Trans- Shs Float32.45M Perf Month5.39%
Income- PEG- EPS next Q-0.98 Inst Own55.81% Short Float1.83% Perf Quarter4.31%
Sales- P/S- EPS this Y-47.10% Inst Trans- Short Ratio3.72 Perf Half Y36.78%
Book/sh11.95 P/B10.67 EPS next Y-28.40% ROA- Target Price147.92 Perf Year32.83%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range63.81 - 135.58 Perf YTD32.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.94% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low99.84% ATR4.69
Employees103 Current Ratio- Sales Q/Q480.50% Oper. Margin- RSI (14)53.37 Volatility3.85% 3.16%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.40 Prev Close133.80
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume159.31K Price127.52
Recom1.70 SMA202.47% SMA501.43% SMA20022.80% Volume222,989 Change-4.69%
Jan-18-19Resumed SunTrust Buy
Jan-04-19Initiated Morgan Stanley Overweight
Dec-17-18Initiated Goldman Buy
Dec-14-18Initiated Wolfe Research Outperform
Jun-29-18Initiated Nomura Buy $161
Apr-09-18Initiated SunTrust Buy $125
Jan-29-18Reiterated JMP Securities Mkt Outperform $74 → $87
May-22-19 07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
01:00AM  argenx announces pipeline expansion and argenx 2021 vision to build integrated immunology company at 2019 R&D Day GlobeNewswire
May-02-19 06:43PM  Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks GuruFocus.com
Apr-25-19 02:38PM  Did Hedge Funds Drop The Ball On argenx SE (ARGX) ? Insider Monkey
Apr-13-19 07:41AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-03-19 05:35AM  Has argenx SE (EBR:ARGX) Got Enough Cash? Simply Wall St.
Feb-28-19 07:00AM  argenx SE ADR to Host Earnings Call ACCESSWIRE
Feb-04-19 01:00AM  argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire
01:00AM  argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology GlobeNewswire
Jan-23-19 07:55AM  Today's Research Reports on Trending Tickers: Editas Medicine and argenx ACCESSWIRE
Jan-22-19 01:52AM  Who Has Been Selling argenx SE (EBR:ARGX) Shares? Simply Wall St.
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +5.38%
Dec-03-18 04:09AM  Dutch firm argenx, J&J affiliate to collaborate on cancer therapy Reuters +13.49%
01:00AM  argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia GlobeNewswire
01:00AM  argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110) GlobeNewswire
Nov-01-18 09:15AM  argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire +20.05%
Oct-25-18 02:04AM  Is argenx SEs (EBR:ARGX) Liquidity Good Enough? Simply Wall St.
01:00AM  argenx reports third quarter 2018 financial results and provides business update GlobeNewswire
Oct-09-18 01:00AM  argenx awarded 2.6 million VLAIO grant to explore new applications of ABDEG technology GlobeNewswire
Sep-21-18 04:01PM  argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million GlobeNewswire
Sep-18-18 08:46PM  argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering GlobeNewswire -6.90%
08:44AM  The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga
Sep-17-18 04:21PM  argenx announces launch of proposed public offering in the United States GlobeNewswire
01:01AM  argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia GlobeNewswire
Sep-06-18 01:01AM  argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis GlobeNewswire
Aug-29-18 01:01AM  argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis GlobeNewswire
Aug-22-18 10:50AM  Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug Benzinga
03:47AM  AbbVie doubles down on cancer project with biotech group Argenx Reuters
02:01AM  argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody GlobeNewswire
Aug-09-18 04:06PM  argenx to Present at 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 01:01AM  argenx reports second quarter business update and half-year 2018 financial results GlobeNewswire
Jul-26-18 01:06AM  argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018 GlobeNewswire
Jul-24-18 04:01PM  argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation GlobeNewswire
Jul-17-18 01:01AM  argenx receives milestone payment from strategic collaboration with Shire GlobeNewswire
Jun-28-18 01:01AM  argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire
01:00AM  argenx receives second preclinical milestone payment under its development agreement with AbbVie GlobeNewswire
Jun-20-18 01:02AM  argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris GlobeNewswire
Jun-14-18 01:01AM  argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation GlobeNewswire
Jun-12-18 01:01AM  argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018 GlobeNewswire
Jun-06-18 01:02AM  argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis GlobeNewswire
Jun-05-18 04:01PM  argenx selected for BEL 20 Index GlobeNewswire
May-28-18 05:51AM  Is argenx SE (EBR:ARGX) A Financially Strong Company? Simply Wall St.
May-17-18 01:01AM  argenx to Present at Upcoming Investor Conferences GlobeNewswire
May-09-18 01:01AM  argenx reports first quarter 2018 financial results and provides business update GlobeNewswire
May-08-18 04:31AM  argenx announces results of Annual General Meeting of Shareholders GlobeNewswire
May-01-18 10:27AM  Five Stocks To Buy According To Top Biotech-Focused Funds Insider Monkey
Apr-26-18 07:25AM  Blog Exposure - Argenx to Present Complete Data from Phase-2 Clinical Trial of Efgartigimod (ARGX-113) at AAN Annual Meeting ACCESSWIRE
Apr-24-18 01:01AM  argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting GlobeNewswire
01:01AM  argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting GlobeNewswire
Apr-12-18 01:01AM  argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112 GlobeNewswire +5.82%
Apr-09-18 01:01AM  argenx appoints Keith Woods as Chief Operating Officer GlobeNewswire +6.73%
Apr-03-18 01:01AM  argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting GlobeNewswire
Apr-02-18 09:22AM  3 Biotech Stocks Hitting New Highs Investopedia
Mar-26-18 09:57PM  argenx announces Annual General Meeting of Shareholders on May 8, 2018 GlobeNewswire
09:00AM  argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe GlobeNewswire
08:28AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
01:01AM  argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe GlobeNewswire
Mar-22-18 02:01AM  argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases GlobeNewswire
Mar-16-18 02:01AM  argenx awarded 2.5 million VLAIO grant to identify novel therapeutic antibodies GlobeNewswire
Mar-12-18 02:04AM  argenx SEs (EBR:ARGX) Profit Outlook Simply Wall St.
Mar-06-18 01:01AM  argenx to Present at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 01:01AM  argenx reports fourth quarter business update and full year 2017 financial results GlobeNewswire +6.97%
01:01AM  argenx reports fourth quarter business update and full year 2017 financial results GlobeNewswire
Feb-22-18 01:01AM  argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018 GlobeNewswire
Dec-18-17 04:02PM  argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million GlobeNewswire
04:01PM  argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million GlobeNewswire
Dec-13-17 07:28PM  argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering GlobeNewswire
07:27PM  argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering GlobeNewswire
06:01AM  argenx announces size of proposed public offering in the United States updated to 3.5 million ADSs GlobeNewswire
Dec-11-17 04:12PM  argenx announces launch of proposed public offering in the United States GlobeNewswire +78.88%
04:11PM  argenx announces launch of proposed public offering in the United States GlobeNewswire
01:06AM  argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting GlobeNewswire
01:06AM  argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting GlobeNewswire
01:01AM  argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis GlobeNewswire
01:01AM  argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis GlobeNewswire
Nov-13-17 01:02AM  argenx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-17 06:02AM  argenx announces results of extraordinary shareholders' meeting 2017 GlobeNewswire
Nov-02-17 02:01AM  argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017 GlobeNewswire
Oct-30-17 02:02AM  argenx launches Phase I trial with subcutaneous formulation of ARGX-113 GlobeNewswire
Oct-26-17 01:05AM  argenx reports third quarter 2017 financial results and provides business update GlobeNewswire
01:02AM  argenx reports third quarter 2017 financial results and provides business update GlobeNewswire
Sep-26-17 01:01AM  argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris GlobeNewswire
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis. The company has license and collaboration agreements with AbbVie S.A.R.L.; Cilag GmbH International; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.